AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04235166 — intervention group
Intervention type: OTHER
Intervention: New risk scores
Description: New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
Study NCT00651300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib/Valdecoxib
Description: A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
Study NCT00651300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
Study NCT02252107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
Study NCT01307878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy ± targeted therapy
Description: Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
Study NCT01504139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase
Description: when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
Study NCT01504139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase
Description: hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
Study NCT01504139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase
Description: LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
Study NCT01504139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase
Description: The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 100 mg
Description: ZSP1273 tablet administered orally once daily under fasted condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 200 mg
Description: ZSP1273 tablets administered orally once daily under fasted condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 200 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 400 mg
Description: ZSP1273 tablets administered orally once daily in the fasting state
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 400 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 600 mg
Description: ZSP1273 tablets administered orally once daily under fasted condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 600 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 900 mg
Description: ZSP1273 tablets administered orally once daily in the fasting state
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 900 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 1200 mg
Description: ZSP1273 tablets administered orally once daily in the fasting state
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1200 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: ZSP1273 tablets administered orally once daily under fasted or fed condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 Low Dose
Description: ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 Median Dose
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Study NCT03679143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 High Dose
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Study NCT00869908 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00869908 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00869908 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT01133704 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Study NCT01133704 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: APC-Placebo
Study NCT04845880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Description: Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Study NCT00720070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Patients undergo PET/CT scan
Study NCT00720070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: positron emission tomography/computed tomography
Description: Patients undergo PET/CT scan
Study NCT00720070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo neck dissection
Study NCT00720070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo neck dissection
Study NCT02693457 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
Study NCT02693457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drain
Description: The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
Study NCT02475772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and doxorubicin
Description: The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
Study NCT02475772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cisplatin and doxorubicin
Description: intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
Study NCT00136214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR brain and neuropsychiatric tests
Study NCT03060369 — intervention group
Intervention type: DEVICE
Intervention: CareGuide™ device
Description: CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
Study NCT02778022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE
Description: PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
Study NCT03114085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
Study NCT03114085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
Study NCT03114085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
Study NCT03351088 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DVC ligation
Description: Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
Study NCT03082469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb
Description: Two consecutive 24h treatments with the CytoSorb-device
Study NCT03974802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A contact lens
Description: Contact Lens
Study NCT03974802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A contact lens
Description: Contact Lens
Study NCT04230343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-benefit message
Description: A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
Study NCT04230343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Other-benefit message
Description: A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
Study NCT01273909 — intervention group
Intervention type: PROCEDURE
Intervention: Perforator Flap Breast Reconstruction
Description: perforator flap breast reconstruction with or without vascularized lymph node transfer
Study NCT01273909 — intervention group
Intervention type: PROCEDURE
Intervention: Vascularized Lymph Node Transfer
Description: perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
Study NCT03263715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Prefilled Syringe [Actemra]
Description: Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
Study NCT03263715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Weekly administration of Placebo subcutaneous from Baseline to Week 16.
Study NCT03263715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoids
Description: Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
Study NCT03263715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
Study NCT00006929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV
Study NCT00006929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00006929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00006929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00006929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01065558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Tablets, once daily, for two weeks up to 200 mg/day
Study NCT04056949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel/Albumin-Bound Paclitaxel
Description: Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
Study NCT04056949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IBI308
Description: IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
Study NCT04712409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single anastomosis duodeno-ileal bypass
Description: Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
Study NCT04712409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliopancreatic diversion with duodenal switch
Description: Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
Study NCT04712409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SADI-S as a revisional procedure
Description: In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
Study NCT04712409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPD-DS as a revisional procedure
Description: In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
Study NCT02763319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (RTX)
Description: Rituximab: Dose: 375 mg/m2 IV
Study NCT02763319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
Study NCT02763319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine (BEN)
Study NCT02763319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine (BEN)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r
Description: Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors
Description: NRTIs for 26 weeks (A) or 24 weeks (B)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoside Reverse Transcriptase Inhibitors
Description: NRTIs for 26 weeks (A) or 24 weeks (B)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week (48 weeks)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week (48 weeks)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day (48 weeks)
Study NCT00437476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day (48 weeks)
Study NCT00335517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur
Description: An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
Study NCT00787163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amnioinfusion
Description: serial amnioinfusions aimed at restoring amniotic fluid volume
Study NCT00578279 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dehydrated alcohol
Description: subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
Study NCT00578279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydrated alcohol
Description: subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
Study NCT03313531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin Generation Assay
Description: Inter lab variation and level of agreement will be determined
Study NCT03313531 — intervention group
Intervention type: DRUG
Intervention: Treatment with recombinant coagulation factor
Description: To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
Study NCT04582279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
Study NCT01222312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, d1 every 3 weeks
Study NCT01222312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1 every 2 weeks
Study NCT01222312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, d1 every 3 weeks
Study NCT01222312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1 every 2 weeks
Study NCT01431313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitrite
Description: Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
Study NCT02586311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/5mg
Description: Once a day, 8 weeks
Study NCT02586311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg Placebo
Description: Once a day, 8 weeks